Roche/Exelixis Get First Cobimetinib Approval
This article was originally published in Scrip
Executive Summary
The Swiss regulatory agency Swissmedic has become the first in the world to approve Roche (Genentech) /Exelixis' selective MEK inhibitor cobimetinib (as Cotellic) for use in combination with Roche's BRAF inhibitor vemurafenib (Zelboraf) as a treatment for patients with advanced melanoma.